STOCK TITAN

22nd Century Group Announces Partial Adjournment of Annual Meeting for Proposal 2, All Other Proposals Passed

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
22nd Century Group, Inc. conducted a special meeting of stockholders to vote on Proposal 2, which aims to increase the number of authorized shares of common stock. The meeting was adjourned to provide more time for stockholders to vote on the proposal, with the reconvened meeting scheduled for February 15, 2024. The company's Chairman and CEO, Larry Firestone, expressed gratitude for the support received and highlighted efforts to streamline operations, reduce costs, and extend the company's balance sheet runway. The goal is to make the company self-sufficient by improving tobacco business margins and increasing returns from assets. Despite progress on various initiatives, Proposal 2 is deemed crucial for addressing strategic needs as the company transitions to self-sustaining operations. Stockholders who have not yet voted are encouraged to do so over the Internet.
Positive
  • None.
Negative
  • None.

The proposal to increase the number of authorized shares of common stock by 22nd Century Group is a strategic move that could have significant implications for the company's capital structure and financing flexibility. An increase in authorized shares typically enables a company to raise additional capital, potentially through equity offerings, which can be used to fund operations, reduce debt, or pursue strategic acquisitions. However, it also poses a dilution risk for existing shareholders, as the issuance of new shares can decrease the value of existing shares.

From a financial standpoint, the company's focus on reducing operating costs and extending its cash runway suggests an attempt to improve its financial position and operational efficiency. The emphasis on enhancing tobacco business margins and increasing VLN sales channels indicates a targeted approach to revenue growth. These efforts, combined with a successful shareholder vote on Proposal 2, could position the company for a more stable financial future and potentially improve investor confidence.

The tobacco industry is highly competitive and subject to stringent regulations. 22nd Century's strategic pivot to concentrate on tobacco operations and improve margins suggests a response to these industry challenges. The company's efforts to increase sales channels and channel support for VLN, a reduced nicotine tobacco product, align with current trends in health-conscious consumer behavior and regulatory shifts towards harm reduction in tobacco products.

Investors should note that the success of these initiatives will likely depend on consumer adoption rates, competitive responses and regulatory developments. The outcome of Proposal 2 could further impact the company's market strategy by providing additional resources to support these initiatives or to explore new opportunities that could enhance the company's competitive position.

The adjournment of the Special Meeting regarding Proposal 2 indicates that 22nd Century Group is seeking broader shareholder support for a significant corporate action. Legally, this move is permissible and often used to allow additional time for shareholder engagement and voting. The legal implications of increasing the authorized share count include potential changes to shareholder rights and corporate governance structures.

Furthermore, the company's adherence to SEC regulations by filing a Definitive Proxy Statement and providing a record date for eligible voters demonstrates compliance with corporate governance standards. Investors should be aware that such corporate actions, while common, require careful consideration of the associated legal and governance aspects, as they can influence shareholder value and company control dynamics.

Transforming Business into Lean Operating Base, Extending Cash Runway, Shareholder Meeting to Re-convene February 15

Mocksville, North Carolina--(Newsfile Corp. - January 24, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII) (the "Company" or "22nd Century"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced that the Company conducted its January 24, 2024 special meeting of stockholders (the "Meeting") and adjourned the Meeting solely with respect to Proposal 2 set forth in its Definitive Proxy Statement (the "Proxy Statement") previously filed with the Securities and Exchange Commission. Proposal 2 is a proposal to increase the number of authorized number of shares of common stock. All other proposals were passed at the Special Meeting with strong support from stockholders.

"We sincerely appreciate the support of our stockholders on these important items as we work to swiftly effect a turnaround of the business," stated Larry Firestone, Chairman and Chief Executive Officer of 22nd Century. "In the seven weeks since I joined the Company, we have fully focused the business on our tobacco operations, implemented aggressive operating cost reductions and extended our balance sheet runway. We are also actively working to improve our tobacco business margins and increase the returns from those assets as we work to make this company self-sufficient, including efforts to increase the channels and channel support for VLN sales. While I am pleased with the progress on these and other initiatives we have underway, Proposal 2 is still critically important to ensuring that the Company can address any strategic needs as we bridge to self-sustaining operations as quickly as possible. We hope that the adjournment will enable additional shareholders to vote for this proposal, or those who may have voted against to reverse their vote and support our efforts to complete the turnaround process."

The Company has adjourned the Special Meeting solely with respect to Proposal 2 to provide its stockholders additional time to vote on Proposal 2. The Special Meeting will resume with respect to Proposal 2 at 11:00 a.m. Eastern Time on February 15, 2024. The reconvened meeting will be held at 11988 El Camino Real, Suite 400, San Diego, CA 92130. The record date for determining stockholders eligible to vote at the Special Meeting will remain the same. To date, more than 48% of all shares outstanding as of the record date have voted in favor of the proposal.

Stockholders as of close of business on December 6, 2023, the record date for the Special Meeting, who have not yet voted are encouraged to vote over the Internet at http://www.proxyvote.com/.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN® at tryvln.com.

###

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 9, 2023 and Quarterly Reports on Form 10-Q filed May 9, 2023, August 14, 2023 and November 6, 2023. All information provided in this press release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/195525

The purpose of the special meeting was to vote on Proposal 2, which aimed to increase the number of authorized shares of common stock.

The reconvened meeting for Proposal 2 is scheduled for February 15, 2024, at 11:00 a.m. Eastern Time.

The company has fully focused on its tobacco operations, implemented aggressive operating cost reductions, and extended its balance sheet runway.

Proposal 2 is considered crucial to address strategic needs as the company transitions to self-sustaining operations.

Stockholders who have not yet voted are encouraged to vote over the Internet at http://www.proxyvote.com/.
22nd Century Group Inc

NASDAQ:XXII

XXII Rankings

XXII Latest News

XXII Stock Data

Tobacco Manufacturing
Manufacturing
Link
Miscellaneous, Health Technology, Biotechnology, Manufacturing, Tobacco Manufacturing

About XXII

with the mission of reducing the harm caused by smoking, 22nd century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. goodrich tobacco company and hercules pharmaceuticals are wholly-owned subsidiaries focusing on (i) premium cigarettes and potentially reduced risk tobacco products (with up to 97% less nicotine than conventional cigarettes), and (ii) the x-22 prescription smoking cessation aid in development. 22nd century's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.